Rapalink-1
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Rapalink-1 is a drug which acts as an inhibitor of the enzyme mechanistic target of rapamycin (mTOR). It is a dimeric molecule consisting of rapamycin joined to a desalkyl derivative of sapanisertib by a linker group. Since both of these products inhibit mTOR but through action at distinct binding sites on the mTOR complex, it exhibits a dual mTOR inhibitory activity and has been suggested for applications as an anti-aging drug or for treatment of some forms of cancer.[1][2][3][4]
| |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C91H138N12O24 |
| Molar mass | 1784.165 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rapalink-1 is synthesized using click chemistry, specifically through a copper-catalyzed azide-alkyne cycloaddition to join rapamycin and sapanisertib, an mTOR active-site inhibitor via a polyethylene glycol linker.[2]
